Dr Reddy’s CFO Outlines Growth Plans Around Semaglutide and Abatacept
CFO MV Narasimham said growth plans include a semaglutide relaunch in Canada, a biosimilar pipeline, expansion in India and growth at Aurigene. The body is truncated after noting the move follows recent developments.
Dr Reddy’s Laboratories is gearing up for a fresh growth cycle with the relaunch of semaglutide in Canada, a pipeline of biosimilars, a steadily expanding India franchise and the fast-growing Aurigene contract research and manufacturing business, CFO MV Narasimham has said.The move follows recent d…